[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635908":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":26,"locations":35,"responsibleParty":66,"collaborators":69,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":74,"sex":79,"minAge":80,"maxAge":18,"enrollmentInfo":81,"targetDuration":18,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":93,"overallStatus":99,"whyStopped":18,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"University Hospital, Akershus","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Natriuresis-guided decongestion","EXPERIMENTAL","In the intervention arm, intravenous loop diuretics will be administered twice daily, and urinary sodium concentration will be measured two hours after each dose. If urinary sodium is less than 70 mmol\u002FL, the subsequent diuretic dose will be doubled, with additional diuretic agents added if maximum loop diuretic dosing is reached.",[13],"Other: Natriuresis-guided escalation of loop diuretics",{"label":15,"type":16,"description":17,"interventionNames":18},"Treatment as usual","NO_INTERVENTION","Standard care, decongestive strategy left at the discretion of the treating physician",null,[20],{"type":6,"name":21,"description":11,"armGroupLabels":22,"otherNames":23},"Natriuresis-guided escalation of loop diuretics",[9],[24,25,9],"Intervention","Natriuresis-guided therapy",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":18,"email":31},"Kristian Berge, MD, PhD","CONTACT","+47 41283128","kristian.berge@ahus.no",{"name":33,"role":29,"phone":18,"phoneExt":18,"email":34},"Peder L Myhre, MD, PhD","p.l.myhre@medisin.uio.no",[36,48],{"facility":37,"status":18,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":18,"geoPoint":18,"contacts":43},"Akershus University Hospital","Lørenskog","Akershus","1478","Norway","NO",[44,45],{"name":28,"role":29,"phone":30,"phoneExt":18,"email":31},{"name":46,"role":47,"phone":18,"phoneExt":18,"email":18},"Kristian Berge, MD PhD","PRINCIPAL_INVESTIGATOR",{"facility":49,"status":18,"city":50,"state":51,"zip":52,"country":41,"countryCode":42,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Østfold Hospital Trust","Sarpsborg","Østfold fylke","1714",{"type":54,"coordinates":55},"Point",[56,57],11.10962,59.28391,{"lat":57,"lon":56},[60,64],{"name":61,"role":29,"phone":62,"phoneExt":18,"email":63},"Kristin M Kvakkestad, MD PhD","+47 69860000","Kristin.Marie.Kvakkestad@so-hf.no",{"name":61,"role":65,"phone":18,"phoneExt":18,"email":18},"SUB_INVESTIGATOR",{"type":47,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Kristian Berge","MD, PhD",[70],{"name":71,"class":6},"Ostfold Hospital Trust","100635908","vexus-assessment-and-natriuresis-guided-diuretic-therapy-in-acute-heart-failure-100635908",false,"NCT07558798","Vexus Assessment and Natriuresis-guided Diuretic Therapy in Acute Heart Failure","VANTAGE-HF","Inclusion Criteria:\n\n* Age \\>18 years\n* Hospitalization with AHF, either de novo or worsening of chronic HF\n* Able to provide written informed consent\n* Requirement of intravenous loop diuretic treatment as judged by the treating physician\n\nExclusion Criteria:\n\n* Dyspnea primarily due to non-cardiac causes\n* Advanced renal disease or estimated glomerular filtration rate (eGFR) \\\u003C 20 mL\u002Fmin\u002F1.73m2 at screening or on-going dialysis.\n* Enrollment in another study interfering with the treatment algorithm of the current study\n* Inability to follow the treatment protocol\n* Language barriers requiring the need for an external interpreter\n* Pregnant or nursing (lactating) women\n* Very short life expectancy (\\\u003C30 days)","ALL","18 Years",{"count":82,"type":83},270,"ESTIMATED","INTERVENTIONAL",[86],"NA","This study evaluates whether natriuresis-guided diuretic therapy improves outcomes in patients with acute heart failure (AHF) and severe congestion. All patients hospitalized with AHF will be screened using Venous Excess Ultrasound (VExUS) and randomized 1:1 to either natriuresis-guided escalation of loop diuretics or standard care. The primary endpoint, evaluated in patients with VExUS grade 3 (severe congestion), is a hierarchical composite (win ratio) of 90-day mortality, 90-day rehospitalization, and hospital length of stay. Key secondary endpoints (hierarchical) include (1) difference in win ratio between patients with VExUS 3 versus VExUS 0-2 at hospital admission (assessed by interaction testing and statistically tested only if the primary endpoint is significant) and (2) win ratio (primary endpoint) tested among patients with VExUS 0-2 at hospital admission (statistically tested only if the first key seconday endpoint is significant). Exploratory endpoints include in-hospital clinical, hemodynamic, and biochemical outcomes (mortality, eGFR, NT-proBNP, NYHA class, VExUS score, natriuresis\u002Fdiuresis, and patient-reported dyspnea), associations between congestion markers (VExUS, FibroScan, lung ultrasound, clinical score, and NT-proBNP), as well as quality of life at 90 days, GDMT optimization score at discharge, and long-term time to readmission and mortality assessed through registry linkage.",[89,90,91,92],"Venous Congestion","Heart Failure Acute","VExUS","Diuretics",[94,95,96,97,98],"loop diuretics","heart failure","acute heart failure","vexus","congestion","NOT_YET_RECRUITING","2026-04-23",{"date":102,"type":103},"2026-04-30","ACTUAL",{"date":105,"type":83},"2026-04",{"date":107,"type":83},"2028-06",{"name":5,"class":6},2]